Exelixis Inc (NAS:EXEL)
$ 20.91 -0.32 (-1.51%) Market Cap: 6.09 Bil Enterprise Value: 5.33 Bil PE Ratio: 32.52 PB Ratio: 2.90 GF Score: 91/100

Exelixis Inc at Piper Sandler Healthcare Conference Transcript

Nov 28, 2023 / 04:00PM GMT
Release Date Price: $21.05 (-2.59%)
Joseph Michael Catanzaro
Piper Sandler & Co., Research Division - Director & Senior Biotech Analyst

Okay. Great. Maybe we'll go ahead and get started here. Thanks, everybody, for joining us or tuning in here at Piper Sandler's Annual Healthcare Conference. I'm Joe Catanzaro, one of the Piper's biotech analyst. It's my pleasure to kick off this section with Exelixis. Joining us is their SVP of Strategy, Andrew Peters. Andrew, thanks so much for joining us.

Questions & Answers

Joseph Michael Catanzaro
Piper Sandler & Co., Research Division - Director & Senior Biotech Analyst

Maybe we could just sort of jump right into questions here and start off with a high level one. I know there's been a lot of recent effort at Exelixis around sort of building up the pipeline and diversifying away from cabo. So maybe you could speak to the overall strategy for the pipeline, what you see as the most capital efficient way to bring those assets into the clinic and establish proof of concept, and then maybe we could sort of tick through some assets

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot